BENTIROMIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H20N2O5
Molecular Weight	404.4153
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C3=CC=CC=C3)C=C1

InChI

InChIKey=SPPTWHFVYKCNNK-FQEVSTJZSA-N

InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C23H20N2O5
Molecular Weight	404.4153
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6371722
Curator's Comment: description was created based on several sources, including: http://www.medicatione.com/?c=drug&s=chymex&ingredient=bentiromide | http://edudrugs.com/C/Chymex/more.html | https://en.wikipedia.org/wiki/Bentiromide

Bentiromide (Chymex) is a diagnostic agent that was approved for the diagnosis of pancreatic exocrine insufficiency. It is given by mouth as a noninvasive test. The amount of p-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the United States or Canada.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Chymotrypsin 1 Target ID: Chymotrypsin Sources: https://www.ncbi.nlm.nih.gov/pubmed/3258344 \| https://www.ncbi.nlm.nih.gov/pubmed/6371722	Substrate 661

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pancreatic exocrine insufficiency 1 Sources: http://edudrugs.com/C/Chymex/more.html	Diagnostic		Approved 8583	CHYMEX Approved Use Chymex is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. Launch Date 1983

Doses

Dose	Population	Adverse events
5 g single, oral Highest studied dose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: https://pubmed.ncbi.nlm.nih.gov/6603385	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/6603385	Other AEs: Nausea, Vomiting... Other AEs: Nausea Vomiting Diarrhea Sources: https://pubmed.ncbi.nlm.nih.gov/6603385

AEs

AE	Dose	Population
Diarrhea	5 g single, oral Highest studied dose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: https://pubmed.ncbi.nlm.nih.gov/6603385	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/6603385
Nausea	5 g single, oral Highest studied dose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: https://pubmed.ncbi.nlm.nih.gov/6603385	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/6603385
Vomiting	5 g single, oral Highest studied dose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: https://pubmed.ncbi.nlm.nih.gov/6603385	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/6603385

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31263	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31263
MolPort	MolPort-006-127-559	https://www.molport.com/shop/molecule-link/MolPort-006-127-559
ZINC	ZINC000000608204	http://zinc15.docking.org/substances/ZINC000000608204

PubMed

Title	Date	PubMed
A case of lipomatous pseudohypertrophy of the pancreas diagnosed by typical imaging.	2010-07-05	20601816
Let it flow: Morpholino knockdown in zebrafish embryos reveals a pro-angiogenic effect of the metalloprotease meprin alpha2.	2010-01-21	20098618
Animal models of chronic pancreatitis.	2010	21197438
Influence of chronic ethanol consumption on extra-pancreatic secretory function in rat.	2009-10	22666702
Metalloprotease meprin beta in rat kidney: glomerular localization and differential expression in glomerulonephritis.	2008-05-28	18509531
The metalloprotease meprinbeta processes E-cadherin and weakens intercellular adhesion.	2008-05-14	18478055
Measurement of extra-pancreatic secretory function by 13C-dipeptide breath test.	2007-06	17543847
Can measurement of chemokines become useful biological and functional markers of early-stage chronic pancreatitis?	2007-01	17238032
Pancreaticoduodenectomy versus Frey's procedure for chronic pancreatitis: preliminary data on outcome and pancreatic function.	2007	17952526
Significance of pancreatic exocrine function in the perioperative management of pancreatoduodenectomy.	2006-11-08	17086890
The outcome of a long-term follow-up of pancreatic function after recovery from acute pancreatitis.	2006-09-10	16998241
[The role of fecal elastase-1 in pancreatic diseases].	2006-04	16780673
Value of magnetic resonance cholangiopancreatography with secretin stimulation in the evaluation of pancreatic exocrine function after pancreaticogastrostomy.	2004	15754047
Pancreatoduodenectomy for chronic pancreatitis with an inflammatory mass of pancreatic head: preoperative and postoperative functional assessment.	2003-12-31	14696501
Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy.	2003-10	14508128
Review article: Pancreatic function testing.	2003-03-15	12641496
Human meprin beta: O-linked glycans in the intervening region of the type I membrane protein protect the C-terminal region from proteolytic cleavage and diminish its secretion.	2003-02-01	12387727
The assessment of pancreatic exocrine function by bentiromide test in patients with chronic portal vein thrombosis.	2002-11	12409829
Which is a less invasive pancreatic head resection: PD, PPPD, or DPPHR?	2001-02	11281176
Pancreatic polypeptide secretion in patients with chronic pancreatitis and after pancreatic surgery.	2001	12067221
The bentiromide test for pancreatic exocrine insufficiency.	1984-03-01	6371722

Patents

Sample Use Guides

In Vivo Use Guide

500-mg dose. Immediately after dosing, 250 ml of water are given, then another 500 ml of water two to six hours after dosing. Urine is collected for six hours after dosing.

Route of Administration: Oral

In Vitro Use Guide

The concentration of bound tyrosine in the secretion is greater (P < 0-05) during perfusion with Bz-tyr-PABA at 2.35 mmol/l than in the N-free controls and is even greater (P < 0-001) with this compound at 18.8 mmol/I. Therefore some transport of bound tyrosine, as either benzoyl-tyrosine or intact Bz-Tyr-PABA, has occurred. However, the net transport of total tyrosine from the Bz-Tyr-PABA at 2.35 mmol/l is only 1.4% of that from tyrosyl-leucine at the same concentration.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:10:12 GMT 2025` Edited by `admin` on `Mon Mar 31 18:10:12 GMT 2025`
Record UNII	239IF5W61J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PFD

Preferred Name

English

BENTIROMIDE

Official Name

English

BENZOIC ACID, 4-((2-(BENZOYLAMINO)-3-(4-HYDROXYPHENYL)-1-OXOPROPYL)AMINO)-, (S)-

Systematic Name

English

BTPABAPFT

Code

English

Bentiromide [WHO-DD]

Common Name

English

BTPABA, PFT

Code

English

BTPABA PFT

Code

English

CHYMEX

Brand Name

English

bentiromide [INN]

Common Name

English

E-2663

Code

English

BENTIROMIDE [MART.]

Common Name

English

BENTIROMIDE [ORANGE BOOK]

Common Name

English

BENTIROMIDE [JAN]

Common Name

English

(S)-P-(.ALPHA.-BENZAMIDO-P-HYDROXYHYDROCINNAMAMIDO)BENZOIC ACID

Systematic Name

English

BTPABA-PFT

Code

English

BENTIROMIDE [USAN]

Common Name

English

BENTIROMIDE [MI]

Common Name

English

BENTIROMIDE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

V04CK03